Anti-Human OSCAR Antibody (SAA1864)

Catalog No.

RHN02901

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Osteoclast-associated receptor, Osteoclast-associated immunoglobulin-like receptor, Polymeric immunoglobulin receptor 3, PIgR-3, hOSCAR, Poly-Ig receptor 3, PIgR3, OSCAR

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q8IYS5

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1864

Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences., PMID:40434685

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial., PMID:40413024

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma., PMID:40387836

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC., PMID:40323213

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)., PMID:40311183

Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome., PMID:40277027

Assessment of the suitability of the dried blood spot (DBS) samples for detection of Treponemal antibodies using in vitro assays., PMID:40257136

Retrospective multicentric survival analysis of patients receiving TPEx regimen as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma., PMID:40220661

Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies., PMID:40186886

Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial., PMID:40179522

Engineering Genome-Free Bacterial Cells for Effective SARS-COV-2 Neutralisation., PMID:40042439

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial., PMID:39979665

Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity., PMID:39945979

Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial., PMID:39864364

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia., PMID:39814982

Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation., PMID:39791147

Epidemiological and genetic factors affecting severe epizootic hemorrhagic disease in Spanish Holstein cattle during the Southern Europe outbreak of 2023., PMID:39788199

Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience., PMID:39721045

Allergen-Specific Immunotherapy and Trained Immunity., PMID:39641571

Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer., PMID:39530624

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study., PMID:39460719

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)., PMID:39442070

Bone impairment in atypical hemolytic and uremic syndrome treated by long-term eculizumab., PMID:39422762

Anti-OAcGD2 antibody in combination with ceramide kinase inhibitor mediates potent antitumor cytotoxicity against breast cancer and diffuse intrinsic pontine glioma cells., PMID:39395135

A sensitive assay for measuring whole-blood responses to type I IFNs., PMID:39312669

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial., PMID:39298147

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer., PMID:39155847

Human cerebrospinal fluid monoclonal CASPR2 autoantibodies induce changes in electrophysiology, functional MRI, and behavior in rodent models., PMID:39142424

Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510)., PMID:39077795

Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar)., PMID:38954912

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer., PMID:38918555

Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab., PMID:38864457

Antibody-displaying extracellular vesicles for targeted cancer therapy., PMID:38769158

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France., PMID:38733172

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial., PMID:38716626

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab., PMID:38703428

Lessons From Prospective Longitudinal Follow-up of a French APECED Cohort., PMID:38605470

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial., PMID:38573643

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer., PMID:38568692

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study., PMID:38547895

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?, PMID:38489858

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial., PMID:38447379

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group., PMID:38443333

Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma., PMID:38405866

Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial., PMID:38395212

Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus., PMID:38378550

METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors., PMID:38199147

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study., PMID:38118368

Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1., PMID:38112858

Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86., PMID:38071989

Document Download

Anti-Human OSCAR Antibody (SAA1864).pdf